Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Protalix BioTherapeutics Inc
PLX | US
2.29
USD-0.01
-0.43%
PLX | US
About Protalix BioTherapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
2.29
Open
2.31
High
2.33
Low
2.29
Protalix BioTherapeutics Inc. a biopharmaceutical company engages in the development production and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States Australia Canada Israel Brazil Russia Turkey and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102 a therapeutic protein candidate for the treatment of Fabry disease; PRX-115 a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119 a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack New Jersey. Protalix BioTherapeutics Inc. is a subsidiary of Protalix Ltd.
View LessPLX | US
Risk
89.1
Sharpe
-0.09
Luna's Score
39/100
Recommendation
Sell
Luna says (PLX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
32.7%1 month
89.1%3 months
75.5%6 months
76.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
1.76
Price to book
2.80
Debt to equity
0.92
Debt to assets
0.29
Ent. to EBITDA
5.63
Ent. to rev.
1.61
PEG
-0.10
Other Fundamentals
EBITDA
-13.53M
MarketCap
168.41M
MarketCap(USD)
168.41M
Div. yield
-
Op. margin
-18.01
Erngs. growth
-39.20
Rev. growth
-61.60
Ret. on equity
-43.49
Short ratio
20.34
Short perc.
4.45
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.28
Range1M
0.89
Range3M
1.22
Volumes: Market Activity
Rel. volume
0.44
Price X volume
955.31K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 5.63 | - | Expensive |
| Ent. to Revenue | 1.61 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.80 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 75.54 | - | Par |
| Debt to Equity | 0.92 | -1.23 | Expensive |
| Debt to Assets | 0.29 | 0.25 | Par |
| Market Cap | 168.41M | - | Emerging |
